Obinutuzumab in hematologic malignancies: lessons learned to date.
AffiliationInstitute of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester
MetadataShow full item record
AbstractThe routine use of anti-CD20 monoclonal antibodies (mAbs) has improved patient outcomes in CD20-positive non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Despite the clinical success achieved with rituximab, relapses are still common with further improvements in anti-CD20 mAb efficacy required. Many novel anti-CD20 antibodies are in development, but obinutuzumab is currently the only type II glycoengineered anti-CD20 mAb in clinical testing. Obinutuzumab has increased antibody-dependent cell-mediated cytotoxicity, reduced complement-dependent cytotoxicity and enhanced direct non-apoptotic cell death. In preclinical models, obinutuzumab induced superior tumor remission compared with rituximab at the equivalent dose levels, and was active in rituximab-refractory tumors. Obinutuzumab exhibits encouraging efficacy as monotherapy in NHL, and combined with chemotherapy in relapsed/refractory NHL and treatment-naïve symptomatic CLL. In a recent randomized, phase III trial in patients with untreated comorbid CLL, overall response rate was significantly greater (78% vs. 65%, P<0.0001) and median progression-free survival was significantly prolonged (26.7 vs. 15.2months, P<0.0001) for obinutuzumab plus chlorambucil vs. rituximab plus chlorambucil. Obinutuzumab is a type II anti-CD20 antibody that utilizes distinct mechanisms of action relative to type I antibodies like rituximab and has led to significant clinical improvement over rituximab in a phase III trial in CLL. Further trials are ongoing to determine whether such improvements in outcome will be seen in CD20-positive B-cell malignancies.
CitationObinutuzumab in hematologic malignancies: Lessons learned to date. 2015: Cancer Treat Rev
JournalCancer Treatment Reviews
- Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
- Authors: Goede V, Klein C, Stilgenbauer S
- Issue date: 2015
- Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
- Authors: Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M
- Issue date: 2014 Mar 20
- Obinutuzumab for the treatment of chronic lymphocytic leukemia.
- Authors: Rogers KA, Jones JA
- Issue date: 2014 Jun
- Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas.
- Authors: Gabellier L, Cartron G
- Issue date: 2016 Apr
- Update on obinutuzumab in the treatment of B-cell malignancies.
- Authors: Illidge T, Cheadle EJ, Donaghy C, Honeychurch J
- Issue date: 2014 Oct